Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy

In Vivo

Volumn 18, Issue 1, 2004, Pages 81-100

  Bodey, Bela ^a,b,e   Siegel, Stuart E ^a,b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e NONE   (United States)

Author keywords

Adhesion molecules; Anterior pituitary; Antigen presenting cell; AP; APC; Birbeck granules; CD34+ hematopoietic stem cell; Cytokines; DC; Dendritic cell; Folliculo stellate cells (FSCs); GM CSF; Granule associated marker (Lag); Granulocyte macrophage colony stimulating factor; IDC; Immunophenotype; Interdigitating cell; Interleukin 12 (IL 12); Interleukin 2 (IL 2); Interleukin 4 (IL 4); Interleukin 6 (IL 6); IP; Langerhans cells; Langerin (CD207); LCs; Major histocompatibility complex (MHC) class II molecules; MIIC (MHC class II enriched compartment, exosomes); MoAb; Monoclonal antibody; Neuroendocrine immunoregulation; TAA; Tumor associated antigen

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CD11B ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; COMPLEMENT RECEPTOR; FC RECEPTOR; GLYCOPROTEIN P 15095; IDIOTYPIC ANTIBODY; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; LECTIN RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN S 100; T6 ANTIGEN; TUMOR VACCINE; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL MOTILITY; CELL SELECTION; CELL SPECIFICITY; CELL STRUCTURE; CELL TRANSFORMATION; CLINICAL TRIAL; DENDRITIC CELL; GENE DELIVERY SYSTEM; GENE THERAPY; GENE VECTOR; HOST CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LANGERHANS CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL SELECTION; NONHUMAN; PRIMARY IMMUNE RESPONSE; REVIEW; SIDE EFFECT;

EID: 1342326199     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (227)

1. Wu L, Scollay R, Egerton M et al: CD4 expressed on earliest T-lineage precursor cells in the adult murine thymus. Nature 349: 71-74, 1991.
2. Wu L, Li CL and Shortman K: Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med 184: 903-911, 1996.
3. Shortman K and Caux C: Dendritic cells development: multiple pathways to nature's adjuvants. Stem Cells 15: 409-419, 1997.
4. Shortman K and Wu L: Parentage and heritage of dendritic cells. Blood 97: 3325, 2001.
5. Wu L, D'Amico A, Hochrein H et al: Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98: 3376-3382, 2001.
6. Shortman K and Liu YJ: Mouse and human dendritic cell subtypes. Nat Rev Immunol 2: 151-161, 2002.
7. O'Keeffe M, Hochrein H, Vremac D et al: Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmocytoid pre-DC2 and CD11+ DC1 precursors. Blood 101: 1453-1459, 2003.
8. Tan PS, Gavin AL, Barnes N et al: Unique monoclonal antibodies define expression of FcgammaRI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 170: 2549-2556, 2003.
9. Kim YJ and Broxmeyer HE: 4-IBB ligand stimulation enhances myeloid dendritic cell maturation from human umbilical cord blood CD34(+) progenitor cells. J Hematother Stem Cell Res 11: 895-903, 2002.
10. Nestle FO, Banchereau J and Hart D: Dendritic cells: on the move from bench to bedside. Nat Med 7: 761-765, 2001.
11. Anjuere F, Martinez del Hoyo G, Martin P and Ardavin C: Langerhans cells develop from a lymphoid-committed precursor. Blood 96: 1633-1637, 2000.
12. Bednar B: Dendritic resident cells and their immunohistologic determination. Ceskoslov Patologie 31: 9-16, 1995.
13. Paglia P, Girolomoni G, Robbiati F, Granucci F and Ricciardi-Castagnoli P: Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo. J Exp Med 178: 1893-1901, 1993.
14. Lenz A, Heine M, Schuler G and Romani N: Human and murine dermis contain dendritic cells, isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 92: 2587-2596, 1993.
15. Steinman RM and Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137: 1142-1162, 1973.
16. Markgraf R, von Gaudecker B and Müller-Hermelink HK: The development of the human lymph node. Cell Tissue Res 225: 387-413, 1982.
17. Witmer MD and Steinman RM: The anatomy of peripheral lymphoid organs with emphasis on accessory cells: light-microscopic immunocytochemical studies of mouse spleen, lymph node and Peyer's patch. Am J Anat 170: 4655-4681, 1984.
18. Bodey B, Bodey B Jr and Kaiser HE: Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. In Vivo 11: 351-370, 1997.
19. von Gaudecker B and Müller-Hermelink HK: Ontogeny and organization of the stationary non-lymphoid cells in the human thymus. Cell Tissue Res 207: 287-306, 1980.
20. Kaiserling E, Stein H and Muller-Hermelink HK: Interdigitating reticulum cells in the human thymus. Cell Tiss Res 155: 47-55, 1974.
21. Crivellato E, Mallardi F, Basa M and Zweyer M: Osmiumzinc iodide reacts with interdigitating cells in the mouse lymph nodes and spleen. Z mikroskop-anat Forsch 104: 476-484, 1990.
22. Crivellato E, Baldini G, Basa M and Fusaroli P: The three-dimensional structure of interdigitating cells. Italian J Anat Embryol 98: 243-258, 1993.
23. Kelly RH, Balfour BM, Armstrong JA and Griffiths S: Functional anatomy of lymph nodes, II. Peripheral lymphborne mononuclear cells. Anat Rec 190: 5-22, 1978.
24. Kamperdijk EWA, de Leeuw JHS and Hoefsmit ECM: Lymph node macrophages and reticulum cells in the immune response; the secondary response to paratyphoid vaccine. Cell Tissue Res 227: 277-290, 1982.
25. Fossum S and Vaalard JL: The architecture of rat lymph nodes. I. Combined light and electronmicroscopy of lymph node cell types. Anat Embryol 167: 229-246, 1983.
26. Hart DNJ and Fabre JW: Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissue of rat heart and other tissues, but not brain. J Exp Med 154: 347-361, 1981.
27. Hart DNJ and McKenzie JL: Interstitial dendritic cells. Int Rev Immunol 6: 128-149, 1990.
28. Klug H and Mager B: Ultrastructure and function of interdigitating cells in the guinea pig thymus. Acta Morph Acad Sci Hung 27: 11-19, 1979.
29. Klug H: Elektronenmikroskopische Untersuchungen zur Phagocytose strahlengeschädigter Lymphozyten im Thymus von Ratten. Z Zellforsch 68: 43-56, 1965.
30. Duijvestijn AM and Kamperdijk EW: Birbeck granules in interdigitating cells of thymus and lymph node. Cell Biol Int Rep 6: 655, 1982.
31. Duijvestijn AM, Sminia T, Kohler YG, Janse EM and Hoefsmit EC: Rat thymus micro-environment: an ultrastructural and functional characterization. Adv Exp Med Biol 149: 441-446, 1982.
32. Duijvestijn AM, Kohler YG and Hoefsmit EC: Interdigitating cells and macrophages in the acute involuting rat thymus. An electron-microscopic study on phagocytic activity and population development. Cell Tiss Res 224: 291-301, 1982.
33. Miyazawa T, Sato C and Kojima K: Thymic phagocytosis and reduction in the negative surface charge of thymocytes after X irradiation. Radiat Res 79: 622-629, 1979.
34. Higley HR and O'Morchoe CC: Morphometric analysis of thymic medullary non-lymphoid cell changes during postnatal development. Dev Comp Immunol 8: 711-719, 1984.
35. van Ewijk W, Verzijden JH, van der Kwast TH and Luijcx-Meijer SW: Reconstitution of the thymus dependent area in the spleen of lethally irradiated mice. A light and electron microscopical study of the T-cell microenvironment. Cell Tiss Res 149: 43-60, 1974.
36. Heusermann U, Stutte HJ and Müller-Hermelink HK: Interdigitating cells in the white pulp of the human spleen. Cell Tiss Res 153: 415-417, 1974.
37. Ferreira-Marques J: Systema sensitivum intra-epidermicum. Die Langerhansschen Zellen als Rezeptoren des hellen Schmerzes: Doloriceptores. Arch Dermatol Syph 193: 191-250, 1951.
38. Niebauer G: Über die interstitiellen Zellen der Haut. Hautarzt 7: 123-126, 1956.
39. Richter R: Studien zur Neurohistologie der nervösen vegetativen Peripherie der Haut bei verschiedenen chronischen infektiösen Granulomen mit besonderer Berücksichtigung der Langerhansschen Zellen; Tuberkolosen der Haut. Arch Klin Exp Dermatol 202: 466-495, 1956.
40. Richter R: Studien zur Neurohistologie der nervösen vegetativen Peripherie der Haut bei verschiedenen chronischen infektiösen Granulomen mit besonderer Berücksichtigung der Langerhansschen Zellen; tertiäre Syphilide der Haut. Arch Klin Exp Dermatol 202: 496-508, 1956.
41. Richter R: Studien zur Neurohistologie der nervösen vegetativen Peripherie der Haut bei verschiededen chronischen infektiösen Granulomen mit besonderer Berücksichtigung der Langerhansschen Zellen; Leishmaniosis cutis. Arch Klin Exp Dermatol 202: 509-517, 1956.
42. Richter R: Studien zur Neurohistologie der nervösen vegetativen Peripherie der Haut bei verschiedenen chronischen infektiösen Granulomen mit besonderer Berücksichtigung der Langerhansschen Zellen; Lepra. Arch Klin Exp Dermatol 202: 518-555, 1956.
43. Niebauer G: Über die Dendritenzellen bei Vitiligo. Dermatologica 130: 317-324, 1965.
44. Niebauer G und Sekido N: Über die Dendritenzellen der Epidermis. Eine Studie über die Langerhans-Zellen in der normalen und ekzematösen Haut des Meerschweinchens. Arch Klin Exp Dermatol 222: 23-42, 1965.
45. Masson P: My conception of cellular nevi. Cancer 4: 9-38, 1951.
46. Billingham RE and Medawar PB: "Desensitization" to skin homografts by injections of donor skin extracts. Ann Surg 137: 444-449, 1953.
47. Fan J and Hunter R: Langerhans cells and the modified technic of gold impregnation by Ferreira-Marques. J Invest Dermatol 31: 115-121, 1958.
48. Fan J, Schoenfeld RJ and Hunter R: A study of the epidermal clear cells with special references to their relationship to the cells of Langerhans. J Invest Dermatol 32: 445-450, 1959.
49. Billingham RE and Silvers WK: Re-investigation of the possible occurrence of maternally induced tolerance in guinea pigs. J Exp Zool 160: 221-224, 1965.
50. Billingham RE and Silvers WK: Some biological differences between thymocytes and lymphoid cells. Wistar Inst Sympos Monogr 2: 41-51, 1964.
51. Schuler G and Steinman RM: Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 161: 526-546, 1985.
52. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G and Steinman RM: Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166: 1484-1498, 1987.
53. + hematopoietic progenitor cells. Blood 87: 1292-1302, 1996.
54. Ardavin C, Wu L, Li CL and Shortman K: Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 362: 761-763, 1993.
55. Galy A, Travis M, Cen D and Chen B: T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 3: 459-473, 1995.
56. + human thymic precursors can be traced by the differential expression of CD44. J Exp Med 181: 475-483, 1995.
57. dim cells in the human thymus can differentiate into T, natural killer, and dendritic cells but are distinct from pluripotent stem cells. Blood 87: 5196-5206, 1996.
58. Langerhans P: Über die Nerven der menschlichen Haut. Virchow's Arch A (Pathol Anat) 44: 325-338, 1868.
59. Silberberg I: Apposition of mononuclear cells to Langerhans cells in contact allergic reactions: an ultrastructural study. Acta Dermatol Venereol 53: 1-12, 1973.
60. Birbeck MS, Breathnach AS and Everall JD: An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. J Invest Dermatol 37: 51-64, 1961.
61. Silberberg I, Baer RL and Rosenthal SA: Circulating Langerhans cells in a dermal vessel. Acta Dermato-Venereol 54: 81-85, 1974.
62. Silberberg-Sinakin I, Fedorko ME, Baer RL et al: Langerhans cells: target cells in immune complex reactions. Cell Immunol 32: 400-416, 1977.
63. Silberberg-Sinakin I, Gigli I, Baer RL and Thorbecke GJ: Langerhans cells: role in contact hypersensitivity and relationship to lymphoid dendritic cells and to macrophages. Immunol Rev 53: 203-232, 1980.
64. Bucana CD, Munn CG, Song MJ, Dunner K Jr and Kripke ML: Internalization of Ia molecules into Birbeck granule-like structures in murine dendritic cells. J Invest Dermatol 99: 365-373, 1992.
65. Henkes W, Syha J and Reske K: Nucleotide sequence of rat invariant gamma chain cDNA clone pLRgamma34.3. Nucleic Acids Res 16: 11822, 1988.
66. Bakke O and Dobberstein B: MHC class II associated invariant chain contains a sorting signal for endosomal compartments. Cell 63: 707-716, 1990.
67. Lotteau V, Teyton L, Peleraux A et al: Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348: 600-605, 1990.
68. Naujokas MF, Morin M, Anderson MS, Peterson M and Miller J: The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74: 257-268, 1993.
69. Hashimoto K and Tarnowski WM: Some new aspects of the Langerhans cell. Arch Dermatol 97: 450-464, 1968.
70. Hashimoto K: Langerhans' cell granule. An endocytotic organelle. Arch Dermatol 104: 148-160, 1971.
71. Olah I, Dunay C, Rohlich P and Toro I: A special type of cells in the medulla of the rat thymus. Acta Biol Acad Sci Hung 19: 97-113, 1968.
72. van Haelst U: Light and electron microscopic study of the normal and pathological thymus of the rat. I. The normal thymus. Zeitschr Zellforsch Mikroskop Anat 77: 534-553, 1967.
73. van Haelst U: Light and electron microscopic study of the normal and pathological thymus of the rat. II. The acute thymic involution. Zeitschr Zellforsch Mikroskop Anat 80: 153-182, 1967.
74. Warchol JB, Brelinska R and Jaroszewski J: Granules of Langerhans cells in the thymus contain gold. Experientia 40: 75-76, 1984.
75. Zelickson AS: The Langerhans cell. J Invest Dermatol 44: 201-212, 1965.
76. Breathnach AS and Wyllie LM: Electron microscopy of melanocytes and Langerhans cells in human fetal epidermis at fourteen weeks. J Invest Dermatol 44: 51-60, 1965.
77. Wolff K: The fine structure of the Langerhans cell granule. J Cell Biol 35: 468-473, 1967.
78. Wolff K: The Langerhans cell. Curr Prob Dermatol 4: 79-145, 1971.
79. Plzak J, Holikova Z, Dvorankova B et al: Analysis of binding of mannosides in relation to langerin (CD207) in Langerhans cells of normal and transformed epithelia. Histochem J 34: 247-253, 2002.
80. Rowden G: Immuno-electron microscopic studies of surface receptors and antigens of human Langerhans cells. Br J Dermatol 97: 593-608, 1977.
81. Rowden G, Lewis MG and Sullivan AK: Ia antigen expression on human epidermal Langerhans cells. Nature 268: 247-248, 1977.
82. Rowden G: Expression of Ia antigens on Langerhans cells in mice, guinea pigs, and man. J Invest Dermatol 75: 22-31, 1980.
83. Veerman AJ: On the interdigitating cells in the thymus-dependent area of the rat spleen: a relation between the mononuclear phagocyte system and T-lymphocytes. Cell Tiss Res 148: 247-257, 1974.
84. Nossal GJ, Abbot A, Mitchell J and Lummus Z: Antigens in immunity. XV. Ultrastructural features of antigen capture in primary and secondary lymphoid follicles. J Exp Med 127: 277-290, 1968.
85. Steinman RM and Witmer MD: Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 75: 5132-5136, 1978.
86. Berman B and Gigli I: Complement receptors on guinea pig epidermal Langerhans cells. J Immunol 124: 685-690, 1980.
87. Hammerling GJ and McDevitt HO: Antigen-binding structures on the surface of T lymphocytes. Israel J Med Sci 11: 1331-1341, 1975.
88. Klein J and Hauptfeld V: Ia antigens: their serology, molecular relationships, and their role in allograft reactions. Transplant Rev 30: 83-100, 1976.
89. Shreffler DC and David CS: The H-2 major histocompatibility complex and the I immune response region: genetic variation, function, and organization. Adv Immunol 20: 125-195, 1975.
90. Nagao S, Inaba S and Iijima S: Langerhans cells at the sites of vaccinia virus inoculation. Arch Dermatol Res/Archiv fur Dermatol Forsch 256: 23-31, 1976.
91. Seite S, Zucchi H, Moyal D et al: Alterations in human epidermal Langerhans cells by ultraviolet radiation: quantitative and morphological study. Br J Dermatol 148: 291-299, 2003.
92. Katz SI, Tamaki K and Sachs DH: Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 282: 324-326, 1979.
93. Frelinger JG, Hood L, Hill S and Frelinger JA: Mouse epidermal Ia molecules have a bone marrow origin. Nature 282: 321-323, 1979.
94. Rausch E, Kaiserling E and Goos M: Langerhans cells and interdigitating reticulum cells in the thymus-dependent region in human dermatopathic lymphadenitis. Virchows Archiv - B Cell Pathol 25: 327-343, 1977.
95. Hoffman-Fezer G, Rodt H and Thierfelder S: Immunohistochemical identification of T- and B-lymphocytes delineated by the unlabeled antibody enzyme method. II. Anatomical distribution of T- and B-cells in lymphoid organs of nude mice. Beitr Pathol 161: 17-26, 1977.
96. Hoffman-Fezer G, Rodt H, Götze D and Thierfelder S: Anatomical distribution of T and B lymphocytes identified by immunohistochemistry in the chicken spleen. Int Arch Allergy Appl Immunol 55: 86-95, 1977.
97. Cocchia D and Miani N: Immunocytochemical localization of the brain-specific S-100 protein in the pituitary gland of adult rat. J Neurocytol 9: 771-782, 1980.
98. Baes M, Allaerts W and Denef C: Evidence for functional communication between folliculo-stellate cells and hormone-secreting cells in perfused anterior pituitary cell aggregates. Endocrinology 120: 685-691, 1987.
99. Vankelecom H, Carmeliet P, van Damme J, Billiau A and Denef C: Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology 49: 102-106, 1989.
100. Nakajima T, Yamaguchi H and Takahashi K: S-100 protein in folliculo-stellate cells of the rat of the pituitary anterior lobe. Brain Res 191: 523-531, 1980.
101. Allaerts W and Denef C: Regulatory activity and topological distribution of folliculo-stellate cells in rat anterior pituitary cell aggregates. Neuroendocrinology 49: 409-418, 1989.
102. Allaerts W, Jeucken PHM, Hofland LJ and Drexhage HA: Morphological, immunohistochemical and functional homologies between pituitary folliculo-stellate cells and lymphoid dendritic cells. Acta Endocrinol 125: 92-97, 1991.
103. Carmeliet P, Vankelecom H, van Damme J, Billiau A and Denef C: Release of interleukin-6 from anterior pituitary cell aggregates: developmental pattern and modulation by glucocorticoids and forskolin. Neuroendocrinology 53: 29-34, 1991.
104. Allaerts W, Jeucken PHM, Bosman FT and Drexhage HA: Relationship between dendritic cells and folliculo-stellate cells in the pituitary: immunohistochemical comparison between mouse, rat and human pituitaries. In: Dendritic Cells in Fundamental and Clinical Immunology (Kamperdijk et al., eds), Plenum Press, New York, 1993, pp 637-642.
105. Takahashi K, Yamaguchi H, Ishizeki J, Nakajima T and Nakazato Y: Immunohistochemical and immunoelectron microscopic localization of S-100 protein in the interdigitating reticulum cells of the human lymph node. Virchows Arch (Cell Pathol) 37: 125-135, 1981.
106. Allaerts W, Jeucken PHM, Bosman FT and Drexhage HA: Relationship between dendritic cells and folliculo-stellate cells in the pituitary: immunohistochemical comparison between mouse, rat and human pituitaries. Adv Exp Med Biol 329: 637-642, 1993.
107. Jones TH and Kennedy RL: Cytokines and hypothalamic-pituitary function. Cytokine 5: 531-538, 1993.
108. Guermonprez P, Valladeau J, Zitvogel L et al: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667, 2002.
109. Steinman RM: Dendritic cells and immune-based therapies. Exp Hematol 24: 859-862, 1996.
110. Robinson JH and Delvig AA: Diversity in MHC class II antigen presentation. Immunology 105: 252-262, 2002.
111. Kalinski P, Hilkens CM, Wierenga EA and Kapsenberg ML: T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20: 561-567, 1999.
112. Banchereau J, Briere F, Caux C et al: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
113. Lutz MB, Assmann CU, Girolomoni G and Ricciardi-Castagnoli P: Different cytokines regulate antigen uptake and presentation of a precursor dendritic cell line. Eur J Immunol 26: 586-594, 1996.
114. Aderem A and Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787, 2000.
115. Visintin A, Mazzoni A, Spitzer JH et al: Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 166: 249-255, 2001.
116. Jurgens M, Wollenberg A, Hanau D et al: Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI. J Immunol 155: 5184-5189, 1995.
117. Regnault A, Lankar D, Lacabanne V et al: Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189: 371-380, 1999.
118. Geissmann F, Launay P, Pasquier B et al: A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J Immunol 166: 346-352, 2001.
119. Thery C and Amigorena S: The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 13: 45-51, 2001.
120. Galluci S and Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol 13: 114-119, 2001.
121. Steinman RM and Nussenzweig MC: Dendritic cells: features and functions. Immunol Rev 53: 127-148, 1980.
122. Steinman RM: The dendritic cell system and its role in immunogenicity. Annual Rev Immunol 9: 271-296, 1991.
123. Monaco JJ: Structure and function of genes in the MHC class II region. Curr Opin Immunol 5: 17-20, 1993.
124. Neefjes JJ and Momburg F: Cell biology of antigen presentation. Curr Opin Immunol 5: 27-34, 1993.
125. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76: 287-299, 1994.
126. Ossevoort MA, Kleijmeer MJ, Nijman HW, Geuze HJ, Kast WM and Melief CJM: Functional and ultrastructural aspects of antigen processing by dendritic cells. Adv Exp Med Biol 378: 227-231, 1995.
127. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994.
128. Nanda NK and Sercarz E: A truncated T cell receptor repertoire reveals underlying immunogenicity of an antigenic determinant. J Exp Med 184: 1037-1043, 1996.
129. Lee PP, Yee C, Savage PA et al: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5: 677-685, 1999.
130. Pardoll DM: Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96: 5340-5342, 1999.
131. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 20: 2665-2676, 2000.
132. Ribas A, Butterfield LH, Glaspy JA and Economou JS: Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther 2: 57-78, 2002.
133. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF and Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480, 1998.
134. + T-helper and a T-killer cell. Nature 393: 474-478, 1998.
135. Grakoui A, Bromley SK, Sumen C et al: The immunological synapse: a molecular machine controlling T cell activation. Science 285: 221-227, 1999.
136. Malissen B: Dancing the immunological two-step. Science 285: 207-208, 1999.
137. Wulfing C and Davis MM: A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science 282: 2266-2269, 1998.
138. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A and Choi Y: TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189: 1025-1031, 1999.
139. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI and Pardoll DM: CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 191: 541-550, 2000.
140. Chinnaiyan AM, Hanna WI, Orth K et al: Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. Curr Biol 6: 897-899, 1996.
141. Froelich CJ, Dixit VM and Yang X: Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases. Immunol Today 19: 30-36, 1998.
142. Inaba K, Swiggard WJ, Inaba M et al: Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 163: 148-156, 1995.
143. Guo M, Gong S, Maric S et al: A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol 61: 729-738, 2000.
144. Kato M, Neil TK, Fearnley DB, McLellan AD, Vuckovic S and Hart DN: Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int Immunol 12: 1511-1519, 2000.
145. Small M and Kraal G: In vitro evidence for participation of DEC-205 expressed by thymic cortical epithelial cells in clearance of apoptotic thymocytes. Int Immunol 15: 197-203, 2003.
146. Jiang W, Swiggard WJ, Heufler C et al: The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375: 151-155, 1995.
147. Mahnke K, Guo M, Lee S et al: The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 151: 673-684, 2000.
148. Valladeau J, Ravel O, Dezutter-Dambuyant C et al: Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12: 71-81, 2000.
149. Geijtenbeek TB, Krooshoop DJ, Bleijs DA et al: DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 1: 353-357, 2000.
150. Geijtenbeek TB, Engering A and Van Kooyk Y: DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J Leukoc Biol 71: 921-931, 2002.
151. Sijts A, Zaiss D and Kloetzel PM: The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol Med 1: 665-676, 2001.
152. Bodey B: Neuroendocrine influence on thymic haematopoiesis via the reticulo-epithelial cellular network. Exp Opin Therap Targets 6: 57-72, 2002.
153. Kasai M, Hirokawa K, Kajino K et al: Difference in antigen presentation pathways between cortical and medullary thymic epithelial cells. Eur J Immunol 26: 2101-2107, 1996.
154. Darsow U and Ring J: Neuroimmune interactions in the skin. Curr Opinion Allergy Clin Immunol 1: 435-439, 2001.
155. Timmerman JM and Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50: 507-529, 1999.
156. Foss FM: Immunologic mechanisms of antitumor activity. Semin Oncol 29(3 Suppl 7): 5-11, 2002.
157. Porgador A and Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995.
158. Bodey B, Bodey B Jr and Kaiser HE: Apoptosis in the mammalian thymus during its normal histogenesis and under various in vitro and in vivo experimental conditions. In Vivo 12: 123-134, 1998.
159. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Over-expression of endoglin (CD105): A marker of breast carcinoma-induced neo-vascularization. Anticancer Res 18: 3621-3628, 1998.
160. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Immunophenotypical (IP) analysis and immunobiology of childhood primary brain tumors. Anticancer Res 19: 2973-2992, 1999.
161. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Immunocytochemical detection of MMP-3 and -10 expression in hepatocellular carcinomas. Anticancer Res 20: 4585-4590, 2000.
162. Bodey B, Bodey B Jr, Gröger AM, Siegel SE and Kaiser HE: Immunocytochemical detection of Homeobox B3, B4, and C6 gene product expression in lung carcinomas. Anticancer Res 20: 2711-2716, 2000.
163. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 15: 57-64, 2001.
164. Bodey B, Siegel SE and Kaiser HE: MAGE-1, a cancer-testis antigen, expression in childhood astrocytomas as an indicator of tumor progression. In Vivo 16: 583-588, 2002.
165. Nair SK, Snyder D, Rouse BT and Gilboa E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70: 706-715, 1997.
166. Paquette RI, Hsu NC, Kiertscher SM et al: Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukocyte Biol 64: 358-367, 1998.
167. Carbone JE and Ohm DP: Immune dysfunction in cancer patients. Oncology (Huntingt) 16: 11-18, 2002.
168. Pioche C, Salomon B and Klatzmann D: Cellules dendritiques et therapie cellulaire antitumorale. Pathologie Biologie 43: 904-909, 1995.
169. Turnbull E and Macpherson G. Immunobiology of dendritic cells in the rat. Immunol Rev 184: 58-68, 2001.
170. Gunzer M and Grabbe S: Dendritic cells in cancer immunotherapy. Crit Rev Immunol 21: 133-145, 2001.
171. Gallucci S, Lolkema M and Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5: 1249-1255, 1999.
172. Gabrilovich DI, Ciernik IF and Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170: 101-110, 1996.
173. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3: 483-490, 1997.
174. Eibl B, Ebner S, Duba C et al: Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 20: 215-223, 1997.
175. Choudhury BA, Liang JC, Thomas EK et al: Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93: 780-786, 1999.
176. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M and Olive D: Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias.. Eur J Immunol 29: 2567-2578, 1999.
177. Ruiz-Cabello F, Cabrera T, Lopez-Nevot MA and Garrido F: Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol 12: 15-24, 2002.
178. Iezzi G, Protti MP, Rugarli C and Bellone M: B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res 56: 11-15, 1996.
179. Amoscato AA, Prenovitz DA and Lotze MT: Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 161: 4023-4032, 1998.
180. Ludewig B, McCoy K, Pericin M et al: Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 166: 3678-3687, 2001.
181. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
182. Wolfers J, Lozier A, Raposo G et al: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303, 2001.
183. Piemonti L, Bernasconi S, Luini W et al: IL-13 supports differentiation of dendritic cells from circulating precursors in concert with GM-CSF. Eur Cytokine Network 6: 245-252, 1995.
184. Barratt-Boyes SM, Henderson RA and Finn OJ: Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood. Immunology 87: 528-534, 1996.
185. Hanada K, Tsunoda R and Hamada H: GM-CSF-induced in vivo
186. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF and TNF alpha. J Exp Med 184: 695-706, 1996.
187. Hochrein H, Jahrling F, Kreyschh HG and Sutter A: Immunophenotypical and functional characterization of bone marrow derived dendritic cells. Adv Exp Med Biol 378: 61-63, 1995.
188. + hemopoietic progenitors. J Immunol 157: 1499-1507, 1996.
189. Yamazaki K and Eyden BP: Ultrastructural and immunohistochemical observations on intralobular fibroblasts of human breast, with observations on the CD34 antigen. J Submicr Cytol Pathhol 27: 309-323, 1995.
190. Nijman HW, Kleijmeer MJ, Ossevoort MA et al: Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med 182: 163-174, 1995.
191. Ossevoort MA, Kleijmeer MJ, Nijman HW, Geuze HJ, Kast WM and Melief CJM: Functional and ultrastructural aspects of antigen processing by dendritic cells. Adv Exp Med Biol 378: 227-231, 1995.
192. Kaplan JM, Yu Q, Piraino ST et al: Induction of antitumor immunity with dendritic cells transduced with adenovirus vectorencoding endogenous tumor-associated antigens. J Immunol 163: 699-707, 1999.
193. Kirk CJ and Mule JJ: Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 11:797-806, 2000.
194. Furumoto K, Arii S, Yamasaki S et al: Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer 87: 665-672, 2000.
195. Hirschowitz EA, Weaver JD, Hidalgo GE and Doherty DE: Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 7: 1112-1120, 2000.
196. Jenne L, Schuler G and Steinkasserer A: Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22: 102-107, 2001.
197. Paul S, Calmels B and Acres RB: Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr Gene Ther 2: 91-100, 2002.
198. Bodey B: Spontaneous regression of neoplasms: new possibilities for immunotherapy. Exp Opin Biolog Therapy 2: 459-476, 2002.
199. Maecker B, Von Bergwelt-Baidon, Anderson KS, Vonderheide RH and Schultze JL: Linking genomics to immunotherapy by reverse immunology - 'immunomics' in the new millennium. Curr Mol Med 1: 609-619, 2001.
200. Onaitis M, Kalady MF, Pruitt S and Tyler DS: Dendritic cell gene therapy. Surg Oncol Clin N Am 11: 645-660, 2002.
201. Scheffer SR, Nave H, Korangy F et al: Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 103: 205-211, 2003.
202. Steinman RM and Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109: 1519-1526, 2002.
203. Gilboa E: Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 23: 101-107, 1996.
204. Topf N and Schmiegel WH: Immuntherapie mit genetisch modifizierten Tumorzellen. Internist 37: 374-381, 1996.
205. Zhang W, He L, Yuan Z et al: Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther 10: 1151-1161, 1999.
206. Klein C, Bueler H and Mulligan RC: Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 191: 1699-1708, 2000.
207. Armstrong TD and Jaffee EM: Cytokine modified tumor vaccines. Surg Oncol Clin N Am 11: 681-696, 2002.
208. Gong J, Avigan D, Chen D et al: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97: 2715-2718, 2000.
209. Xia J, Tanaka Y, Koido S et al: Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 170: 1980-1986, 2003.
210. Schultz J: Success of vaccine offers promise of cervical cancer prevention. J Natl Cancer Inst 95: 102-104, 2003.
211. Shu S and Cohen P: Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 24: 99-100, 2001.
212. Lollini PL, De Giovanni C, Nicoletti G et al: Immunoprevention of colorectal cancer: a future possibility? Gastroenterol Clin N Am 31:1001-1014, 2002.
213. Bell D, Young JW and Banchereau J: Dendritic cells. Adv Immunol 72: 255-324, 1999.
214. Banchereau J, Briere F, Caux C et al: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
215. + progenitors. J Invest Dermatol 109: 738-743, 1997.
216. Rougier N, Schmitt D and Vincent C: IL-4 addition during differentiation of CD34 progenitors delays maturation of dendritic cells while promoting their survival. Eur J Cell Biol 75: 287-293, 1998.
217. Nestle FO, Alijagic S, Gilliet M et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
218. Zitvogel L, Angevin E and Tursz T: Dendritic cell-based immunotherapy of cancer. Ann Oncol 11 (suppl.) 3: 199-205, 2000.
219. Panelli MC, Wunderlich J, Jeffries J et al: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23: 487-498, 2000.
220. Small EJ, Fratesi P, Reese DM et al: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903, 2000.
221. Cohen L, De Moor C, Parker PA and Amato RJ: Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol 7: 119-124, 2002.
222. Tirapu I, Rodriguez-Calvillo M, Qian C et al: Cytokine gene transfer into dendritic cells for cancer treatment. Curr Gene Ther 2: 79-89, 2002.
223. Kugler A, Stuhler G, Walden P et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332-336, 2000.
224. Gitlitz BJ, Figlin RA, Pantuck AJ and Belldegrun AS: Dendritic cell-based immunotherapy of renal cell carcinoma. Curr Urol Rep 2: 46-52, 2001.
225. Veelken H and Osterroth F: Vaccination strategies in the treatment of lymphomas. Oncology 62: 187-200, 2002.
226. Perales MA and Wolchok JD: Melanoma vaccines. Cancer Invest 20: 1012-1026, 2002.
227. Wysocki PJ, Karczewska A and Mackiewicz A: Gene modified tumor vaccines in therapy of malignant melanoma. Otolaryngol Pol 56: 147-153, 2002.